2024年9月20日,生物技术公司诺瓦瓦克斯医药(NVAX)股价盘中大涨6.39%,引发市场关注。分析人士认为,公司最新财报数据向好、行业整体向好及机构对该股看好评级等因素有望提振投资者信心,成为该股当日大涨的主要驱动力。
诺瓦瓦克斯医药近期公布的财报显示,公司实现营业收入4.15亿美元,净利润1.62亿美元,每股收益1.09美元,毛利3.79亿美元,财报数据出色。同时该公司所在的生物技术行业整体上涨2.33%,大环境向好。
此外,机构投行研报方面,共有5家机构给予该股评级,其中40%发出买入评级,40%为持有评级,仅20%为卖出评级,外资看好情绪较为浓厚。同时,诺瓦瓦克斯医药当日交易数据活跃,成交量和振幅均较大,反映资金积极推动上行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.